National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1) (PB 10 of 2020) (Cth)

Case

PB 10 of 2020

National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated 29 January 2020

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

  1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1).

(2)This Instrument may also be cited as PB 10 of 2020.

  1. Commencement

This Instrument commences on 1 February 2020.

  1. Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

  1. Schedule 1, entry for Cefaclor in the form Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

omit from the column headed “Claimed Price”:   7.85        substitute:                10.55

  1. Schedule 1, entry for Cefaclor in the form Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

omit from the column headed “Claimed Price”:   8.25        substitute:                10.75

  1. Schedule 1, entry for Cefaclor in the form Tablet (sustained release) 375 mg (as monohydrate)

omit from the column headed “Claimed Price”:   9.32        substitute:                10.94

  1. Schedule 1, after entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg

Insert:

Dicloxacillin Capsule 250 mg (as sodium) Oral Distaph 250 24 4.30 6.11
Capsule 500 mg (as sodium) Oral Distaph 500 24 7.53 9.35
  1. Schedule 1, after entry for Dorzolamide with timolol in the form Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL

Insert:

Dosulepin Capsule containing dosulepin hydrochloride 25 mg Oral Dothep 25 50 2.39 4.20
Tablet containing dosulepin hydrochloride 75 mg Oral Dothep 75 30 2.39 4.20
  1. Schedule 1, after entry for Hydrocortisone in the form Ointment containing hydrocortisone acetate 10 mg per g, 50 g

Insert:

Tablet 4 mg Oral Hysone 4 50 13.45 16.24
Tablet 20 mg Oral Hysone 20 60 19.20 21.99
Hydromorphone Injection containing hydromorphone hydrochloride 2 mg in 1 mL Injection Dilaudid 5 10.07 13.79
Injection containing hydromorphone hydrochloride 10 mg in 1 mL Injection Dilaudid-HP 5 13.43 17.15
  1. Schedule 1, entry for Levonorgestrel wih Ethinylestradiol in the form Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets [Brand: Levlen ED]

omit from the column headed “Claimed Price”:   8.94        substitute:                9.37

  1. Schedule 1, after entry for Metformin in the form Tablet (extended release) containing metformin hydrochloride 1 g

Insert:

Methyldopa Tablet 250 mg (as sesquihydrate) Oral Aldomet 100 8.18 11.05
  1. Schedule 1, after entry for Oxazepam in the form Tablet 30 mg

Insert:

Oxycodone Tablet containing oxycodone hydrochloride 5 mg Oral Endone 20 1.81 3.67

[10] Schedule 1, entry for Ranitidine

Omit:

Tablet, effervescent, 150 mg (as hydrochloride) Oral Zantac 30 1.81 2.35

[11] Schedule 1, entry for Telmisartan in the form Tablet 40 mg

omit from the column headed “Claimed Price”:   5.15        substitute:                5.83

[12] Schedule 1, entry for Telmisartan in the form Tablet 80 mg

omit from the column headed “Claimed Price”:   8.28        substitute:                8.97

[13] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg‑5 mg (as besilate)

omit from the column headed “Claimed Price”:   5.92        substitute:                6.60

[14] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg‑10 mg (as besilate)

omit from the column headed “Claimed Price”:   6.52        substitute:                7.21

[15] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg‑5 mg (as besilate)

omit from the column headed “Claimed Price”:   9.05        substitute:                9.74

[16] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg‑10 mg (as besilate)

omit from the column headed “Claimed Price”:   9.65        substitute:                10.33

[17] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg‑12.5 mg

omit from the column headed “Claimed Price”:   5.62        substitute:                6.31

[18] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg‑12.5 mg

omit from the column headed “Claimed Price”:   8.79        substitute:                9.48

[19] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg‑25 mg

omit from the column headed “Claimed Price”:   9.26        substitute:                9.94

Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0